Answers are grounded in this paper and cite their sources.
The results of this updated MAIC of elranatamab and teclistamab in TCE/R MM support the findings of the previous MAIC over a longer-term follow-up, now indicating significantly improved PFS, OS, and DoR with elranatamab versus teclistamab.
No takes yet. Share an insight, caveat, or question.
Mol et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: